2nd RNA Editing Summit 2020Industry led meeting on RNA Editing mechanisms Share X2nd RNA Editing Summit 2020https://pharmaphorum.com/events/2nd-rna-editing-summit-2020/
4th Annual Genome Editing USA Congress2 days, 350+ end users, 80+ case studies Share X4th Annual Genome Editing USA Congresshttps://pharmaphorum.com/partner-content/4th-annual-genome-editing-usa-congress/
GSK makes CRISPR play, funding Doudna lab in CaliforniaGlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new Share XGSK makes CRISPR play, funding Doudna lab in Californiahttps://pharmaphorum.com/news/gsk-makes-crispr-play-funding-doudna-lab-in-california/
R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentsNovartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company Share XR&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentshttps://pharmaphorum.com/views-and-analysis/rd-roundup-novartis-crispr-opdivo/
Biotech Verve launches on mission to replace statins with CRISPR gene editing techCould CRISPR gene editing one day replace the need for cholesterol-lowering drugs such as statins? US biotech Verve Share XBiotech Verve launches on mission to replace statins with CRISPR gene editing techhttps://pharmaphorum.com/news/biotech-verve-launches-on-mission-to-replace-statins-with-crispr-gene-editing-tech/
Living the CRISPR dreamCaribou Biosciences, Inc., one of a handful of biotechs working on therapies based around gene editing, is at Share XLiving the CRISPR dreamhttps://pharmaphorum.com/r-d/views-analysis-r-d/living-crispr-dream/
R&D roundup: the ups and downs of CRISPR and Alzheimer’sWhile the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm Share XR&D roundup: the ups and downs of CRISPR and Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/
CRISPR gene editing stocks fall after Editas CEO resignsShares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the Share XCRISPR gene editing stocks fall after Editas CEO resignshttps://pharmaphorum.com/news/crispr-gene-editing-stocks-fall-after-editas-ceo-resigns/
2018 in review: Alzheimer’s falters while oncology shinesGoing into 2018 you might have expected this to be the year of Alzheimer’s drugs, with several promising Share X2018 in review: Alzheimer’s falters while oncology shineshttps://pharmaphorum.com/r-d/views-analysis-r-d/2018-review-alzheimers-research-oncology/
